Oryx Pharmaceuticals to Market CNS Drugs in Canada

By Business Review Editor

Pharma Deals Review: Vol 2002 Issue 28 (Table of Contents)

Published: 2 Sep-2002

DOI: 10.3833/pdr.v2002.i28.1014     ISSN: 1756-7874

Section: Distribution & Marketing



Oryx Pharmaceuticals acquired the Canadian rights from Novartis Pharmaceuticals for central nervous system products such as Anafranil® (clomipramine) for treating depression and obsessive compulsive disorder, and Restoril® (temazipam) for short-term insomnia...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details